Abbott Concludes Former Employees’ Allegations Concerning Michigan Formula Plant ‘Unfounded’

Firm Plans Spending $500M To Build US Facility To Boost Formula Production

Abbott’s Q3 worldwide sales of formula and other pediatric nutritionals were down 24.8% on reported basis. It plans spending $500m on a new formula facility after finding the US “would benefit from more manufacturing capacity and redundancy.”

• Source: Shutterstock

Abbott is done investigating a former employee’s allegations about quality-control problems at its Michigan infant formula plant but impacts on revenues from temporarily shutting down the facility aren’t done with the firm.

Another impact from the shutdown and Abbott’s related recall of three of its major formula brands the firm announced with...

More from Earnings

More from Business